Abstract
PAST: There are no reports of promising biomarkers that predict which cases can be transferred to conversion surgery (CS) after chemotherapy plus nivolumab as first-line treatment for unresectable advanced or recurrent gastric cancer (GC). The purpose of this multicenter retrospective study was to conduct an analysis of real-world data on CS after chemotherapy plus nivolumab as a first-line treatment and to identify predictive biomarkers. PRESENT: We showed the CS transition rate was 11.5%. All CS cases had R0 resection, and the postoperative short-term outcome was acceptable. There were no high-risk Gustave Roussy Immune Score (GRIm-s) cases among those who underwent CS. FUTURE: Although this study was a multicenter study, the number of patients was small. A randomized controlled trial should be conducted for a more detailed study of the significance of CS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
